Note A - Organization and Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, € in Millions				3 Months Ended	12 Months Ended
	Mar. 31, 2019 shares	Sep. 30, 2017 USD ($)	Aug. 07, 2017 shares	Dec. 28, 2018 USD ($)	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2020 EUR (€)	Jul. 01, 2019 USD ($)
Operating Lease, Right-of-Use Asset					$ 18,354,000			$ 20,774,000
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect
Foreign Currency Contract, Asset, Fair Value Disclosure					254,000	2,300,000
Investment Income, Interest					177,000	1,868,000
Impairment of Long-Lived Assets to be Disposed of					0	0
Sales Discounts, Noncash						82,000
Sales, Royalty and Licensing Revenue					12,600,000	16,700,000
Royalty Expense					544,000	686,000
Research and Development Expense, Total					1,800,000	1,800,000
Advertising Expense					$ 1,400,000	$ 1,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares					0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | shares					0	5,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					$ 0	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares						0
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Beta Alanine Raw Material Sale Customers [Member]
Concentration Risk, Percentage					2.50%	8.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage					65.70%	59.40%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | shares					5,000	190,000
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount					$ 1,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares					$ 8.50	$ 11.57
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares					323,904
Restricted Stock [Member] | Juice Plus, Amended and Restated Exclusive Manufacturing Agreement [Member]
Treasury Stock, Shares, Acquired (in shares) | shares	400,000
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares					130,000
Foreign Exchange Contract [Member]
Derivative, Notional Amount					$ 49,400,000		€ 43.5
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					1 year
Minimum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					39 years
Maximum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					5 years
Kaged Muscle LLC [Member] | Notes Receivable [Member]
Notes, Loans and Financing Receivable, Term (Month)		1 year
Financing Receivable, after Allowance for Credit Loss, Current, Total		$ 1,500,000
Notes, Loans and Financing Receivable, Extension Fee				$ 25,000
Notes, Loans and Financing Receivable, Interest Rate, Stated Percentage		15.00%
Investment Income, Interest						$ 104,000
Juice Plus + [Member]
Agreement, Term (Year)			5 years
Juice Plus + [Member] | Restricted Stock [Member]
Stock Issuance Agreement, Shares Agreed to Grant (in shares) | shares			500,000
Sales Discounts, Noncash					$ 0	82,000
Sales Discounts, Cash					1,600,000	395,000
Former Contract Manufacturing Customer [Member]
Accounts Receivable, before Allowance for Credit Loss					$ 3,300,000
Bad Debt Reserve, Percentage of Outstanding Balance					100.00%
Fair Value, Inputs, Level 1 [Member]
Fair Value, Net Asset (Liability), Total					$ 0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Net Asset (Liability), Total					0	0
Retained Earnings [Member]
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect					128,000
AOCI Attributable to Parent [Member]
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect					(128,000)
Other Nonoperating Income (Expense) [Member]
Gain (Loss) on Derivative Instruments, Net, Pretax, Total					$ 864,000	$ 1,600,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset								20,774,000
Operating Lease, Liability, Total								$ 20,900,000